Headline of release should read: Compugen Fourth Quarter 2012 Conference Call Scheduled for Wednesday, February 20, 2013 at 10:00 AM EST
The release reads:
COMPUGEN FOURTH QUARTER 2012 CONFERENCE CALL SCHEDULED FOR WEDNESDAY, FEBRUARY 20, 2013 AT 10:00 AM EST
Compugen Ltd. (
) today announced that the Company will host a conference call at 10:00 AM EST on Wednesday, February 20, 2013 to review fourth quarter 2012 results. The quarterly results will be released on the Company’s website (
), prior to the conference call.
To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-918-0609 internationally. The call will also be available via live webcast through Compugen’s website, located at the following
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-9255-904 internationally. The replay will be available through February 23, 2013.
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the
(by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at